vs
思佳讯（SWKS）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
思佳讯的季度营收约是UNITED THERAPEUTICS Corp的1.2倍（$943.7M vs $790.2M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs 3.8%，领先42.3%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs -1.0%），过去两年UNITED THERAPEUTICS Corp的营收复合增速更高（8.0% vs 2.1%）
思佳讯是总部位于美国加利福尼亚州尔湾的半导体企业，公司股票在纳斯达克全球精选市场挂牌交易，股票代码为SWKS，同时也是标普500指数的成分股之一，在全球射频半导体领域拥有较高市场地位。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
SWKS vs UTHR — 直观对比
营收规模更大
SWKS
是对方的1.2倍
$790.2M
营收增速更快
UTHR
高出8.4%
-1.0%
净利率更高
UTHR
高出42.3%
3.8%
两年增速更快
UTHR
近两年复合增速
2.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $943.7M | $790.2M |
| 净利润 | $35.6M | $364.3M |
| 毛利率 | 40.8% | 86.9% |
| 营业利润率 | 4.5% | 45.1% |
| 净利率 | 3.8% | 46.1% |
| 营收同比 | -1.0% | 7.4% |
| 净利润同比 | -48.2% | 20.9% |
| 每股收益（稀释后） | $0.24 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SWKSUTHR
| Q2 26 | $943.7M | — | ||
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.1B | $790.2M | ||
| Q3 25 | — | $799.5M | ||
| Q2 25 | $965.0M | $798.6M | ||
| Q1 25 | $953.2M | $794.4M | ||
| Q4 24 | $1.1B | $735.9M | ||
| Q3 24 | $1.0B | $748.9M |
净利润SWKSUTHR
| Q2 26 | $35.6M | — | ||
| Q1 26 | $79.2M | — | ||
| Q4 25 | $141.4M | $364.3M | ||
| Q3 25 | — | $338.7M | ||
| Q2 25 | $105.0M | $309.5M | ||
| Q1 25 | $68.7M | $322.2M | ||
| Q4 24 | $162.0M | $301.3M | ||
| Q3 24 | $60.5M | $309.1M |
毛利率SWKSUTHR
| Q2 26 | 40.8% | — | ||
| Q1 26 | 41.3% | — | ||
| Q4 25 | 40.7% | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | 41.6% | 89.0% | ||
| Q1 25 | 41.1% | 88.4% | ||
| Q4 24 | 41.4% | 89.7% | ||
| Q3 24 | 41.9% | 88.9% |
营业利润率SWKSUTHR
| Q2 26 | 4.5% | — | ||
| Q1 26 | 10.0% | — | ||
| Q4 25 | 10.1% | 45.1% | ||
| Q3 25 | — | 48.6% | ||
| Q2 25 | 11.5% | 45.6% | ||
| Q1 25 | 10.2% | 48.2% | ||
| Q4 24 | 16.9% | 48.6% | ||
| Q3 24 | 5.8% | 45.8% |
净利率SWKSUTHR
| Q2 26 | 3.8% | — | ||
| Q1 26 | 7.6% | — | ||
| Q4 25 | 12.9% | 46.1% | ||
| Q3 25 | — | 42.4% | ||
| Q2 25 | 10.9% | 38.8% | ||
| Q1 25 | 7.2% | 40.6% | ||
| Q4 24 | 15.2% | 40.9% | ||
| Q3 24 | 5.9% | 41.3% |
每股收益（稀释后）SWKSUTHR
| Q2 26 | $0.24 | — | ||
| Q1 26 | $0.53 | — | ||
| Q4 25 | $0.95 | $7.66 | ||
| Q3 25 | — | $7.16 | ||
| Q2 25 | $0.70 | $6.41 | ||
| Q1 25 | $0.43 | $6.63 | ||
| Q4 24 | $1.00 | $6.23 | ||
| Q3 24 | $0.36 | $6.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.8B | $7.1B |
| 总资产 | $7.9B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SWKSUTHR
| Q2 26 | — | — | ||
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | $1.3B | $3.0B | ||
| Q1 25 | $1.5B | $3.3B | ||
| Q4 24 | $1.7B | $3.3B | ||
| Q3 24 | $1.6B | $3.3B |
总债务SWKSUTHR
| Q2 26 | — | — | ||
| Q1 26 | $496.6M | — | ||
| Q4 25 | $496.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $496.2M | — | ||
| Q1 25 | $995.1M | — | ||
| Q4 24 | $994.7M | — | ||
| Q3 24 | $994.3M | — |
股东权益SWKSUTHR
| Q2 26 | $5.8B | — | ||
| Q1 26 | $5.8B | — | ||
| Q4 25 | $5.8B | $7.1B | ||
| Q3 25 | — | $6.6B | ||
| Q2 25 | $5.7B | $7.2B | ||
| Q1 25 | $5.9B | $6.8B | ||
| Q4 24 | $6.4B | $6.4B | ||
| Q3 24 | $6.3B | $6.1B |
总资产SWKSUTHR
| Q2 26 | $7.9B | — | ||
| Q1 26 | $7.9B | — | ||
| Q4 25 | $7.9B | $7.9B | ||
| Q3 25 | — | $7.4B | ||
| Q2 25 | $7.7B | $7.9B | ||
| Q1 25 | $7.9B | $7.7B | ||
| Q4 24 | $8.3B | $7.4B | ||
| Q3 24 | $8.3B | $7.1B |
负债/权益比SWKSUTHR
| Q2 26 | — | — | ||
| Q1 26 | 0.09× | — | ||
| Q4 25 | 0.09× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.09× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 0.16× | — | ||
| Q3 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $50.3M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | — | $173.3M |
| 自由现金流率自由现金流/营收 | — | 21.9% |
| 资本支出强度资本支出/营收 | 8.7% | 21.9% |
| 现金转化率经营现金流/净利润 | 1.41× | 0.95× |
| 过去12个月自由现金流最近4个季度 | — | $1.0B |
8季度趋势，按日历期对齐
经营现金流SWKSUTHR
| Q2 26 | $50.3M | — | ||
| Q1 26 | $395.5M | — | ||
| Q4 25 | $200.0M | $346.2M | ||
| Q3 25 | — | $562.1M | ||
| Q2 25 | $314.2M | $191.7M | ||
| Q1 25 | $409.4M | $461.2M | ||
| Q4 24 | $377.2M | $341.2M | ||
| Q3 24 | $476.1M | $377.2M |
自由现金流SWKSUTHR
| Q2 26 | — | — | ||
| Q1 26 | $339.0M | — | ||
| Q4 25 | $144.0M | $173.3M | ||
| Q3 25 | — | $351.6M | ||
| Q2 25 | $252.7M | $129.5M | ||
| Q1 25 | $370.9M | $386.3M | ||
| Q4 24 | $338.2M | $254.5M | ||
| Q3 24 | $393.3M | $300.7M |
自由现金流率SWKSUTHR
| Q2 26 | — | — | ||
| Q1 26 | 32.7% | — | ||
| Q4 25 | 13.1% | 21.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | 26.2% | 16.2% | ||
| Q1 25 | 38.9% | 48.6% | ||
| Q4 24 | 31.7% | 34.6% | ||
| Q3 24 | 38.4% | 40.2% |
资本支出强度SWKSUTHR
| Q2 26 | 8.7% | — | ||
| Q1 26 | 5.5% | — | ||
| Q4 25 | 5.1% | 21.9% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | 6.4% | 7.8% | ||
| Q1 25 | 4.0% | 9.4% | ||
| Q4 24 | 3.6% | 11.8% | ||
| Q3 24 | 8.1% | 10.2% |
现金转化率SWKSUTHR
| Q2 26 | 1.41× | — | ||
| Q1 26 | 4.99× | — | ||
| Q4 25 | 1.41× | 0.95× | ||
| Q3 25 | — | 1.66× | ||
| Q2 25 | 2.99× | 0.62× | ||
| Q1 25 | 5.96× | 1.43× | ||
| Q4 24 | 2.33× | 1.13× | ||
| Q3 24 | 7.87× | 1.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SWKS
暂无分部数据
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
